title: Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
abstract: The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis. Reversible posterior leukoencephalopathy syndrome (RPLS) is a neurologic disorder that has been documented with increased frequency with the use of systemic and biologic agents. We report a case of a 58-year-old man with psoriasis who presented with confusion and memory difficulties after being on treatment with ustekinumab for over six years. Imaging with CT and MRI revealed mild parenchymal edema with the typical appearance and distribution of RPLS, confirming the diagnosis of this condition. This case reports the second case of RPLS associated with ustekinumab treatment, with the only other known case reported during clinical trials. With the increasing use of biologics in patients with moderate to severe psoriasis, it is critical that clinicians are cognizant of this potential associated adverse event. <p><em>J Drugs Dermatol. 2017;16(2):177-179.</em></p>.
authors.forename: Lauren
authors.initials: L
authors.lastname: Dickson
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
mesh_terms: D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced / Q000175:diagnosis*; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003879:Dermatologic Agents; D000069549:Ustekinumab